Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Kodiak Sciences Inc. (KOD) Financial Statements

Free cash flow over the same period: -$159.9M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

KODKodiak Sciences Inc.Follow KOD — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
5.5B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
12 Nov, in 19 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2018
Dec 18
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Research & development0.020.040.110.220.270.210.130.180.20
Operating income-0.03-0.05-0.14-0.27-0.34-0.28-0.19-0.23-0.25
Pre-tax income-0.04-0.05-0.13-0.27-0.33-0.26-0.18-0.23-0.24
Income tax——0.000.000.000.000.000.00—
Net income-0.04-0.05-0.13-0.27-0.33-0.26-0.18-0.23-0.24
Diluted EPS ($)-2.77-1.25-2.91-5.16-6.39-4.97-3.35-4.32-3.86
Diluted shares (bn)————0.0520.0520.0530.053—

USD billions · SEC XBRL

Kodiak Sciences Inc. — questions

What is Kodiak Sciences Inc.'s net income?
-$242.0M over the twelve months to 2026-06-30.
What is Kodiak Sciences Inc.'s free cash flow?
-$159.9M over the twelve months to 2026-06-30.
What are Kodiak Sciences Inc.'s diluted earnings per share?
$-3.86 over the twelve months to 2026-06-30.

Every figure on this page comes from Kodiak Sciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.